This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Example content

Adverse event reporting can be found at the bottom of the page

Optimising Management Of Migraine in Acute Settings: Current Treatment Options Available

Prescribing information can be found at the bottom of the page.


Join us on 30 April 2024 to hear from Dr Amir Jehangir, Consultant in Acute and General Medicine discussing 'Optimising Management Of Migraine in Acute Settings: Current Treatment Options Available' followed by a live interactive Q&A. 

This promotional meeting is organised and funded by Pfizer Ltd for UK HCP's and may include reference to medicines or vaccines promoted by Pfizer.

The content for this meeting has been developed in line with Summary of Product Characteristics for Great Britain and Northern Ireland.

Prescribing information can be found at the bottom of the page.


Join us on 30 April 2024 to hear from Dr Amir Jehangir, Consultant in Acute and General Medicine discussing 'Optimising Management Of Migraine in Acute Settings: Current Treatment Options Available' followed by a live interactive Q&A. 

This promotional meeting is organised and funded by Pfizer Ltd for UK HCP's and may include reference to medicines or vaccines promoted by Pfizer.

The content for this meeting has been developed in line with Summary of Product Characteristics for Great Britain and Northern Ireland.

Event Date30 April 2024 14:15 BSTDuration1 Hr AudienceConsultants, Nurses, Pharmacists, Specialist Registrars {{givenName}}%20{{familyName}}%20has%20shared%20a%20resource%20with%20you%3B%20please%20click%20the%20link%20below%3A%0D%0A%0D%0A{{URL}}%0D%0A%0D%0AThank%20you%2C%0D%0A{{givenName}}%20{{familyName}}
Agenda
Meeting Agenda 14:10 - 14:15Joining & Registration
14:15 - 14:20Welcome & Introduction Amir Jehangir - Dr
14:20 - 15:00Optimising Management Of Migraine in Acute Settings: Current Treatment Options Available Amir Jehangir - Dr
15:00 - 15:15Questions & Answers Amir Jehangir - Dr
15:15Meeting Close
Speakers
Event Speakers
Amir Jehangir, Dr
Amir Jehangir, DrConsultant in Acute and General Medicine, University College London Hospital

Dr Amir Jehangir holds a substantive role as Consultant in Acute and General Medicine at University College London Hospital. He is a Fellow of the Royal College of Physicians and an Associate Professor in Internal Medicine at University College London. 

He has a specialist interest and expertise in thromboembolic disease and responsibilities include developing the Clinical Practice Group for North Central London pulmonary embolism pathway and same day emergency care services. 

He led the task force for the Medical COVID response at The Royal Free Hospital delivering above national figures outcomes for their patient population and has been instrumental in helping UCLH rank first nationally for trainee satisfaction.  

Within his role at Health Education England, Dr Jehangir is the lead training programme director for over 300 internal medicine trainees across Kent, Surrey and Sussex.

 

Vydura®(rimegepant) 

Prescribing Information

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.

PP-NNT-GBR-1611. March 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​